REduCing Immunogenicity to PegloticasE (RECIPE) Study
Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
Pegloticase treatment for chronic refractory gout is limited by immunogenicity. The
investigators propose the REduCing Immunogenicity to PegloticasE (RECIPE) trial to begin to
investigate the question of whether a short course of immune modulating therapy with
mycophenolate mofetil can significantly and safely attenuate immunogenicity to pegloticase
and ensure patients afflicted with chronic refractory gout have better treatment outcomes and
improved quality of life.